Daniel Gonzalez

Has grant

Duke University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Application of Physiologically-Based Pharmacokinetic Modeling to Characterize Drug-Drug Interactions in Infants

Open Date: 2021-05-01

Close Date: 2026-04-30

Grant: Close

Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with Obesity

Open Date: 2018-09-01

Close Date: 2023-07-31

Articles (20)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (12)

Craig Lee

University of North Carolina at Chapel Hill

UNITED STATES

View details

Catherine Bendel

University of Minnesota

UNITED STATES

Duke University

UNITED STATES

View details

Carl Kirkpatrick

Professor

MONASH UNIVERSITY

AUSTRALIA

View details

Cindy Hoi Ting Yeung

Assistant Professor

Dalhousie University

CANADA

View details

Jillian Hurst

Assistant Professor

Duke University School of Medicine

UNITED STATES

View details

Joern-Hendrik Weitkamp

Professor

Vanderbilt University Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daniel Gonzalez

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (20)

Population Pharmacokinetics of Caffeine in Infants with Hypoxic‐Ischemic Encephalopathy: A Phase I, Dose‐Escalating Trial

Leveraging In Silico and Artificial Intelligence Models to Advance Drug Disposition and Response Predictions Across the Lifespan

Characterizing Enoxaparin’s Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population

Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia

Pharmacokinetics of Dexamethasone in Children and Adolescents with Obesity

Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population

Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population

Population Pharmacokinetics of Caffeine in Neonates with Congenital Heart Disease and Associations with Acute Kidney Injury

Population Pharmacokinetics and Model-Based Dose Optimization of Vancomycin in Sudanese Adult Patients with Renal Impairment

Coupling Pre- and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding

Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress‐Testing Renal Function Range in Real World Patients

Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients

Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease

Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research

Use of Real‐World Data and Physiologically‐Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity

Machine learning‐guided covariate selection for time‐to‐event models developed from a small sample of real‐world patients receiving bevacizumab treatment

Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model

Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.

Leveraging Physiologically-Based Pharmacokinetic (PBPK) Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions (DDIs) in the Pediatric Population

External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole

Collaborators (12)

Craig Lee

Catherine Bendel

Daniel Weiner

Zachary Taylor

Christoph Hornik

Matthew Loop

Nigel Key

Elizabeth Thompson

Carl Kirkpatrick

Cindy Hoi Ting Yeung

Jillian Hurst

Joern-Hendrik Weitkamp

Make your next move.